Biomedical Value Fund (BMVF)
Public Equity Funds:
The Biomedical Value Fund (BMVF) is approximately $700 million and completes PIPE investments, structured financings, debt restructurings, and public market purchases of health care stocks with investments of $10 to $50 million. The fund invests in biotechnology and life sciences, consumer health, generic drug, health care services, insurance, medical device, specialty pharmaceutical, pharmaceutical, and workers compensation companies. A key feature of our public equity investing is our leadership role in structured financings (sometimes referred to as "PIPEs").
Great Point Partners is known in the health care field as a leader in health care PIPEs (Private Investments in Public Entities) and has considerable expertise in this form of financing. While many other funds invest only in PIPEs as part of a large syndicate, Great Point Partners seeks to invest $10 to $50 million per financing and is willing to be the sole investor if it is appropriate. Additionally, we participate in restructurings, acquisition financings, and other negotiated investments with public companies.
Management teams of health care companies are encouraged to contact us directly if they would like to meet with us in our offices in Greenwich, Connecticut.